Calithera Biosciences (OTC: CALA)
Calithera Biosciences Return vs. S&P
| 1 Year | 5 Year | 5 Year Annualized | Since IPO |
|---|
Calithera Biosciences Company Info
Calithera Biosciences, Inc. is a clinical stage precision oncology biopharmaceutical company, which engages in developing targeted therapies to redefine treatment for biomarker-specific patient populations. It also focuses on researching small molecule oncology compounds with a biomarker-driven approach that targets genetic vulnerabilities in cancer cells to deliver new therapies for patients suffering from aggressive hematologic. The company was founded by James A. Wells and Susan M. Molineaux on March 9, 2010 and is headquartered in South San Francisco, CA.
News & Analysis
Why Calithera Biosciences Stock Is Plunging Today
The company reported negative results from a clinical trial.
Here's Why Calithera Biosciences, Inc. Rose as Much as 25.2% Today
The tiny pharma stock received an upgrade from a prominent analyst.
3 Stocks That Turned $1,000 Into at Least $2,017 in 12 Months
You don't need a million bucks to have a winning portfolio.
5 Best Biotech Stocks of 2017 So Far
How Alnylam, Puma, Immunogen, Sangamo, and Calithera beat all others to be the best biotech stocks of the year so far.
Here's Why Calithera Biosciences Stock Gained as Much as 16.4% Today
An expanded collaboration with Bristol-Myers Squibb and an update on first-quarter 2017 financials had investors cheering.
Valuation
Earnings Transcripts
Calithera Biosciences (CALA) Q2 2022 Earnings Call Transcript
CALA earnings call for the period ending June 30, 2022.
Calithera Biosciences (CALA) Q1 2022 Earnings Call Transcript
CALA earnings call for the period ending March 31, 2022.
Calithera Biosciences (CALA) Q4 2021 Earnings Call Transcript
CALA earnings call for the period ending December 31, 2021.
Calithera Biosciences, Inc (CALA) Q3 2021 Earnings Call Transcript
CALA earnings call for the period ending September 30, 2021.
Related Stocks
Premium Investing Services
Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.